Supernus Pharmaceuticals (SUPN) Leases: 2019-2025
Historic Leases for Supernus Pharmaceuticals (SUPN) over the last 4 years, with Sep 2025 value amounting to $28.8 million.
- Supernus Pharmaceuticals' Leases was N/A to $28.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.8 million, marking a year-over-year change of. This contributed to the annual value of $24.5 million for FY2024, which is 15.58% down from last year.
- Latest data reveals that Supernus Pharmaceuticals reported Leases of $28.8 million as of Q3 2025, which was up 31.44% from $21.9 million recorded in Q2 2025.
- Supernus Pharmaceuticals' 5-year Leases high stood at $35.4 million for Q4 2021, and its period low was $21.9 million during Q2 2025.
- In the last 3 years, Supernus Pharmaceuticals' Leases had a median value of $26.6 million in 2024 and averaged $26.0 million.
- Its Leases has fluctuated over the past 5 years, first surged by 55.47% in 2021, then declined by 18.27% in 2022.
- Quarterly analysis of 5 years shows Supernus Pharmaceuticals' Leases stood at $35.4 million in 2021, then decreased by 18.27% to $28.9 million in 2022, then increased by 0.31% to $29.0 million in 2023, then dropped by 15.58% to $24.5 million in 2024, then reached $28.8 million in 2025.
- Its Leases was $28.8 million in Q3 2025, compared to $21.9 million in Q2 2025 and $24.5 million in Q4 2024.